300381.SZ
溢多利
SZSE · Healthcare · C 制造业 · CN
CNY 6.21
−1.27%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 842.5M | 832.3M | 826.2M | 796.0M | 1.2B |
| Cost of Revenue | 454.4M | 454.2M | 456.7M | 449.0M | 802.1M |
| Gross Profit | 388.1M | 378.0M | 369.5M | 347.0M | 371.9M |
| Operating Expenses | |||||
| R&D Expense | 105.4M | 105.0M | 109.3M | 99.8M | 99.9M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 99.4M | 98.7M | 91.6M | 97.5M | 159.7M |
| Selling & Marketing Expense | 174.1M | 173.7M | 158.3M | 176.5M | 170.2M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 395.6M | 387.0M | 361.7M | 359.0M | 423.8M |
| Cost and Expenses | 850.0M | 841.3M | 818.4M | 808.0M | 1.2B |
| Operating Income (EBIT) | (3.5M) | (10.1M) | 30.3M | 15.9M | 105.4M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (3.2M) | (16.4M) | 31.8M | 1.3M | 105.1M |
| Income Tax Expense | 3.0M | 2.1M | (169.7K) | 127.2K | 67.5M |
| Bottom Line | |||||
| Net Income | (8.2M) | (19.8M) | 31.1M | (10.7M) | 18.2M |
| Earnings from Cont. Ops | (6.2M) | (18.5M) | 32.0M | 1.2M | 37.5M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (8.2M) | (19.8M) | 31.1M | (10.7M) | 18.2M |
| Per Share | |||||
| Basic EPS | (CN¥0.02) | (CN¥0.04) | CN¥0.06 | (CN¥0.02) | CN¥0.04 |
| Diluted EPS | (CN¥0.02) | (CN¥0.04) | CN¥0.06 | (CN¥0.02) | CN¥0.04 |
| Revenue Per Share | CN¥1.72 | CN¥1.70 | CN¥1.68 | CN¥1.62 | CN¥2.40 |
| Shares | |||||
| Basic Shares Outstanding | 490.6M | 490.8M | 490.4M | 490.9M | 490.1M |
| Diluted Shares Outstanding | 490.6M | 490.8M | 490.4M | 490.9M | 490.1M |
| Profitability Metrics | |||||
| EBITDA | — | 120.8M | 147.1M | 133.8M | 247.9M |
| D&A | — | 130.8M | 116.8M | 117.9M | 142.5M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026